Dapagliflozin: an effective adjunctive treatment in type 1 diabetes.

导出 LinkOut

翻译打印收藏纠错

作者： Ghasem,Yadegarfar ^[1] ; Mark,Livingston ^[2] ; Gabriela,Cortes ^[3] ; Ramadan,Alshames ^[4] ; Kate,Leivesley ^[5] ; Ann,Metters ^[6] ; Linda,Horne ^[6] ; Tom,Steele ^[6] ; Adrian H,Heald ^[6]

作者单位： The School of Medicine and Manchester Academic Health Sciences Centre, University of Manchester, UK. ^[1] Heart Failure Research Center, Cardiovascular Research Institute, & School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran. ^[2] Walsall Manor Hospital, Black Country Pathology Services, Walsall, UK. ^[3] General Directorate of Quality and Health Education, Mexico City, Mexico. ^[4] Biochemistry Department, Faculty of Dentistry, Tripoli University, Libya, Tripoli. ^[5] Vernova Healthcare, Watersgreen Medical Centre, Macclesfield. ^[6] Department of Diabetes and Endocrinology, Salford Royal Hospital, Salford, UK. ^[7]

关键词 HbA1c SGLT2-inhibitor glycaemic control type 1 diabetes

DOI 10.1097/XCE.0000000000000248

PMID 34124604

发布时间 2022-04-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cardiovascular endocrinology & metabolism

2021年10卷2期

132-136页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Dapagliflozin: an effective adjunctive treatment in type 1 diabetes.

Cardiovascular endocrinology & metabolism

相似文献

Cardiovascular endocrinology & metabolism

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Dapagliflozin: an effective adjunctive treatment in type 1 diabetes.

Cardiovascular endocrinology & metabolism

相似文献

Cardiovascular endocrinology & metabolism

相关期刊

检索历史清除